Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study.
Buondonno I, Sassi F, Carignano G, Dutto F, Ferreri C, Pili FG, Massaia M, Nisoli E, Ruocco C, Porrino P, Ravetta C, Riganti C, Isaia GC, D'Amelio P. Buondonno I, et al. Among authors: riganti c. Clin Nutr. 2020 Jul;39(7):2080-2091. doi: 10.1016/j.clnu.2019.10.013. Epub 2019 Oct 18. Clin Nutr. 2020. PMID: 31672329 Free article. Clinical Trial.
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance.
Chegaev K, Rolando B, Cortese D, Gazzano E, Buondonno I, Lazzarato L, Fanelli M, Hattinger CM, Serra M, Riganti C, Fruttero R, Ghigo D, Gasco A. Chegaev K, et al. Among authors: riganti c. J Med Chem. 2016 May 26;59(10):4881-9. doi: 10.1021/acs.jmedchem.6b00184. Epub 2016 May 5. J Med Chem. 2016. PMID: 27120394 Free article.
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors.
Gazzano E, Rolando B, Chegaev K, Salaroglio IC, Kopecka J, Pedrini I, Saponara S, Sorge M, Buondonno I, Stella B, Marengo A, Valoti M, Brancaccio M, Fruttero R, Gasco A, Arpicco S, Riganti C. Gazzano E, et al. Among authors: riganti c. J Control Release. 2018 Jan 28;270:37-52. doi: 10.1016/j.jconrel.2017.11.042. Epub 2017 Dec 2. J Control Release. 2018. PMID: 29191785 Free article.
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E, Buondonno I, Marengo A, Rolando B, Chegaev K, Kopecka J, Saponara S, Sorge M, Hattinger CM, Gasco A, Fruttero R, Brancaccio M, Serra M, Stella B, Fattal E, Arpicco S, Riganti C. Gazzano E, et al. Among authors: riganti c. Cancer Lett. 2019 Aug 1;456:29-39. doi: 10.1016/j.canlet.2019.04.029. Epub 2019 Apr 29. Cancer Lett. 2019. PMID: 31047947 Free article.
Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.
Godel M, Morena D, Ananthanarayanan P, Buondonno I, Ferrero G, Hattinger CM, Di Nicolantonio F, Serra M, Taulli R, Cordero F, Riganti C, Kopecka J. Godel M, et al. Among authors: riganti c. Int J Mol Sci. 2020 Jun 24;21(12):4500. doi: 10.3390/ijms21124500. Int J Mol Sci. 2020. PMID: 32599901 Free PMC article.
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.
Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, Drandi D, Ladetto M, Boccadoro M, Massaia M, Coscia M. Rigoni M, et al. Among authors: riganti c. Oncotarget. 2015 Oct 6;6(30):29833-46. doi: 10.18632/oncotarget.4006. Oncotarget. 2015. PMID: 26284584 Free PMC article.
276 results